Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers

9 Jan 2023

Abstract excerpt

Background: There has been evidence that Polybromo-1 (PBRM1) mutation was closely associated with immunotherapy response in clear cell renal cell carcinoma (ccRCC). However, it remains incompletely unclear whether PBRM1 mutations correlate with ICI response in pan-cancer. Methods: The clinical data and whole exome sequencing (WES) data were collected from seven published immunotherapy studies to evaluate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36699446
DOI: 10.3389/fgene.2022.1066347

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancersPMID 36699446Read ↗

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancerSemantic proximity Read ↗

Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB.Semantic proximity Read ↗

[Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].Semantic proximity Read ↗

Pan-cancer Analysis Identifies LMNB1 as a Target to Redress Th1/Th2 Imbalance and Enhance PARP Inhibitor Response in Human CancersSemantic proximity Read ↗

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.Semantic proximity Read ↗

Significance of PBRM1 mutation in disease progress and drug selection in clear cell renal cell carcinoma.Semantic proximity Read ↗

Pan-cancer analysis identifies LMNB1 as a target to redress Th1/Th2 imbalance and enhance PARP inhibitor response in human cancersSemantic proximity Read ↗

A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.Semantic proximity Read ↗

Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinomaSemantic proximity Read ↗

Prognostic and Immunological Role of RBMX in cancersSemantic proximity Read ↗

An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.